AbbVie's Investigational PanGenotypic Regimen of ABT493 and ABT530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with DirectActing Antivirals

Press/Media: Press / Media

PeriodApr 16 2016

Media coverage

1

Media coverage

  • TitleAbbVie's Investigational PanGenotypic Regimen of ABT493 and ABT530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with DirectActing Antivirals
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date4/16/16
    PersonsFred Poordad